ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 164 filers reported holding ASCENDIS PHARMA A/S in Q3 2023. The put-call ratio across all filers is 1.12 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $480,961,447 | +4.8% | 5,136,282 | -0.1% | 0.04% | +10.5% |
| Q2 2023 | $458,816,846 | -58.5% | 5,140,805 | -50.1% | 0.04% | -25.5% |
| Q1 2023 | $1,104,830,262 | +73.0% | 10,304,330 | +97.1% | 0.05% | -19.0% |
| Q4 2022 | $638,626,318 | +17.2% | 5,229,070 | -0.9% | 0.06% | +10.5% |
| Q3 2022 | $545,096,000 | +10.8% | 5,278,865 | -0.3% | 0.06% | +16.3% |
| Q2 2022 | $492,048,000 | -21.7% | 5,293,120 | -1.2% | 0.05% | -2.0% |
| Q1 2022 | $628,434,000 | -12.8% | 5,354,756 | -0.0% | 0.05% | -5.7% |
| Q4 2021 | $720,536,000 | -16.1% | 5,355,943 | -0.6% | 0.05% | -22.1% |
| Q3 2021 | $859,129,000 | +21.3% | 5,390,099 | +0.1% | 0.07% | +23.6% |
| Q2 2021 | $708,125,000 | +2.2% | 5,382,937 | +0.1% | 0.06% | -6.8% |
| Q1 2021 | $692,732,000 | -22.2% | 5,375,013 | +0.6% | 0.06% | -25.3% |
| Q4 2020 | $890,874,000 | +9.2% | 5,341,609 | +1.1% | 0.08% | -3.7% |
| Q3 2020 | $815,504,000 | +14.9% | 5,284,499 | +10.1% | 0.08% | +5.1% |
| Q2 2020 | $709,710,000 | +32.0% | 4,798,583 | +0.5% | 0.08% | +5.4% |
| Q1 2020 | $537,596,000 | -19.1% | 4,773,963 | +0.0% | 0.07% | +1.4% |
| Q4 2019 | $664,152,000 | +45.0% | 4,773,954 | +0.4% | 0.07% | +32.7% |
| Q3 2019 | $457,956,000 | -15.3% | 4,754,520 | +1.3% | 0.06% | -12.7% |
| Q2 2019 | $540,365,000 | -2.2% | 4,692,706 | -0.0% | 0.06% | -4.5% |
| Q1 2019 | $552,332,000 | +109.7% | 4,692,707 | +11.6% | 0.07% | +83.3% |
| Q4 2018 | $263,333,000 | -10.5% | 4,203,246 | +1.2% | 0.04% | +9.1% |
| Q3 2018 | $294,230,000 | +32.4% | 4,152,262 | +24.3% | 0.03% | +26.9% |
| Q2 2018 | $222,163,000 | -8.8% | 3,339,794 | -10.3% | 0.03% | -10.3% |
| Q1 2018 | $243,584,000 | +67.5% | 3,724,532 | +2.6% | 0.03% | +70.6% |
| Q4 2017 | $145,427,000 | +10.5% | 3,630,224 | 0.0% | 0.02% | +6.2% |
| Q3 2017 | $131,596,000 | +46.4% | 3,630,224 | +12.1% | 0.02% | +45.5% |
| Q2 2017 | $89,907,000 | -0.9% | 3,238,720 | 0.0% | 0.01% | -8.3% |
| Q1 2017 | $90,685,000 | +42.1% | 3,238,720 | +2.7% | 0.01% | +33.3% |
| Q4 2016 | $63,807,000 | +26.3% | 3,152,532 | +25.5% | 0.01% | +28.6% |
| Q3 2016 | $50,507,000 | +51.5% | 2,512,824 | 0.0% | 0.01% | +40.0% |
| Q2 2016 | $33,345,000 | -21.7% | 2,512,824 | +9.4% | 0.01% | -16.7% |
| Q1 2016 | $42,599,000 | +0.6% | 2,296,441 | -0.6% | 0.01% | 0.0% |
| Q4 2015 | $42,333,000 | +89.0% | 2,310,741 | +82.6% | 0.01% | +100.0% |
| Q3 2015 | $22,397,000 | +22.0% | 1,265,394 | +21.2% | 0.00% | +50.0% |
| Q2 2015 | $18,353,000 | +7.8% | 1,043,956 | +6.4% | 0.00% | 0.0% |
| Q1 2015 | $17,026,000 | – | 981,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,909,742 | $911,991,000 | 16.68% |
| Vivo Capital, LLC | 1,797,745 | $277,428,000 | 16.03% |
| Sofinnova Investments, Inc. | 1,109,874 | $171,276,000 | 12.70% |
| Asymmetry Capital Management, L.P. | 81,442 | $12,568,000 | 8.08% |
| Ghost Tree Capital, LLC | 130,000 | $20,062,000 | 5.80% |
| Eversept Partners, LP | 161,004 | $24,846,137 | 5.52% |
| Eventide Asset Management | 1,709,848 | $263,864,000 | 5.16% |
| Avoro Capital Advisors LLC | 1,800,000 | $277,776,000 | 3.95% |
| BERYLSON CAPITAL PARTNERS, LLC | 72,700 | $11,219,000 | 3.93% |
| Spyglass Capital Management LLC | 547,022 | $84,416,000 | 3.90% |